iShares Biotechnology ETF
874 hedge funds and large institutions have $4.85B invested in iShares Biotechnology ETF in 2023 Q4 according to their latest regulatory filings, with 124 funds opening new positions, 177 increasing their positions, 376 reducing their positions, and 73 closing their positions.
70% more first-time investments, than exits
New positions opened: 124 | Existing positions closed: 73
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
5% more funds holding
Funds holding: 833 → 874 (+41)
3% more capital invested
Capital invested by funds: $4.71B → $4.85B (+$142M)
2.4% less ownership
Funds ownership: 67.03% → 64.63% (-2.4%)
53% less repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 376
75% less call options, than puts
Call options by funds: $353M | Put options by funds: $1.42B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMEA
Main Management ETF Advisors
San Francisco,
California
|
+$66.6M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$26.6M |
| 3 |
JP Morgan Chase
New York
|
+$22.5M |
| 4 |
JHU
Johns Hopkins University
Baltimore,
Maryland
|
+$19.7M |
| 5 |
MIM
Miller Investment Management
West Conshohocken,
Pennsylvania
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$153M |
| 2 |
Morgan Stanley
New York
|
-$44M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$39.7M |
| 4 |
MMA
Miracle Mile Advisors
Los Angeles,
California
|
-$36.7M |
| 5 |
Goldman Sachs
New York
|
-$29.6M |
IBB Hedge Fund Activity: Q4 2023 in Review
874 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2023, worth a combined $4.85B — up 3% from $4.71B a quarter earlier.
Buyers outnumbered sellers: 124 funds opened new IBB positions and 73 closed out — a net gain of 51 holders — while 177 added to existing stakes and 376 trimmed.
The largest buyer was Main Management ETF Advisors, opening a new position worth an estimated $66.6M. The largest seller was Bank of America, cutting an estimated $153M.
- 874 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2023, up from 833 in Q3 2023.
- Funds reported $4.85B of iShares Biotechnology ETF stock for Q4 2023, up 3% quarter-over-quarter.
- 124 funds opened new iShares Biotechnology ETF positions in Q4 2023 and 73 closed out, a net change of +51 holders.
- The largest iShares Biotechnology ETF buyer in Q4 2023 was Main Management ETF Advisors, an estimated $66.6M added.
- The largest iShares Biotechnology ETF seller in Q4 2023 was Bank of America, an estimated $153M sold.
Based on aggregated 13F filings for Q4 2023.